The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Histiocytic disorders
Open accessAbstract
The historic term ‘histiocytosis’ meaning ‘tissue cell’ is used as a unifying concept for diseases characterized by pathogenic myeloid cells that share histological features with macrophages or dendritic cells. These cells may arise from the embryonic yolk sac, fetal liver or postnatal bone marrow. Prior classification schemes align disease designation with terminal phenotype: for example, Langerhans cell histiocytosis (LCH) shares CD207 + antigen with physiological epidermal Langerhans cells. LCH, Erdheim–Chester disease (ECD), juvenile xanthogranuloma (JXG) and Rosai–Dorfman disease (RDD) are all characterized by pathological ERK activation driven by activating somatic mutations in MAPK pathway genes. The title of this Primer (Histiocytic disorders) was chosen to differentiate the above diseases from Langerhans cell sarcoma and malignant histiocytosis, which are hyperproliferative lesions typical of cancer. By comparison LCH, ECD, RDD and JXG share some features of malignant cells including activating MAPK pathway mutations, but are not hyperproliferative. ‘Inflammatory myeloproliferative neoplasm’ may be a more precise nomenclature. By contrast, haemophagocytic lymphohistiocytosis is associated with macrophage activation and extreme inflammation, and represents a syndrome of immune dysregulation. These diseases affect children and adults in varying proportions depending on which of the entities is involved. Histiocytic disorders are characterized by proliferation of cells with macrophage or dendritic cell phenotype and intense inflammation. Clinical signs and symptoms depend on the specific disease and the tissues and organs affected.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations
Hyman, D. M., Puzanov, I., Subbiah, V., Faris, J. E., Chau, I., Blay, J.-Y., Wolf, J., Raje, N. S., Diamond, E. L., Hollebecque, A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1502309 · Cited by 1,764
Targeting RAS–ERK signalling in cancer: promises and challenges
Samatar, A. A., & Poulikakos, P. I. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4281 · Cited by 1,163
Origin, homeostasis and function of Langerhans cells and other langerin-expressing dendritic cells
Merad, M., Ginhoux, F., & Collin, M. (2008) · Nature Reviews Immunology · doi:10.1038/nri2455 · Cited by 850
Self-citationHypercytokinemia in familial hemophagocytic lymphohistiocytosis
Henter, J., Elinder, G., Soder, O., Hansson, M., Andersson, B., & Andersson, U. (1991) · Blood · doi:10.1182/blood.v78.11.2918.2918 · Cited by 505
Salvage therapy of refractory hemophagocytic lymphohistiocytosis with alemtuzumab
Marsh, R. A., Allen, C. E., McClain, K. L., Weinstein, J. L., Kanter, J., Skiles, J., Lee, N. D., Khan, S. P., Lawrence, J., Mo, J. Q., et al. (2013) · Pediatric Blood & Cancer · doi:10.1002/pbc.24188 · Cited by 310
Self-citationBenefit of Anakinra in Treating Pediatric Secondary Hemophagocytic Lymphohistiocytosis
Eloseily, E. M., Weiser, P., Crayne, C. B., Haines, H., Mannion, M. L., Stoll, M. L., Beukelman, T., Atkinson, T. P., & Cron, R. Q. (2020) · Arthritis & Rheumatology · doi:10.1002/art.41103 · Cited by 282
Chellapandian, D., Das, R., Zelley, K., Wiener, S. J., Zhao, H., Teachey, D. T., Nichols, K. E., & EBV‐HLH Rituximab Study Group (2013) · British Journal of Haematology · doi:10.1111/bjh.12386 · Cited by 251
A somatic mutation in erythro-myeloid progenitors causes neurodegenerative disease
Mass, E., Jacome-Galarza, C. E., Blank, T., Lazarov, T., Durham, B. H., Ozkaya, N., Pastore, A., Schwabenland, M., Chung, Y. R., Rosenblum, M. K., et al. (2017) · Nature · doi:10.1038/nature23672 · Cited by 210
Johnson, T. S., Terrell, C. E., Millen, S. H., Katz, J. D., Hildeman, D. A., & Jordan, M. B. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1302282 · Cited by 203
The role of the initial bone marrow aspirate in the diagnosis of hemophagocytic lymphohistiocytosis
Gupta, A., Tyrrell, P., Valani, R., Benseler, S., Weitzman, S., & Abdelhaleem, M. (2008) · Pediatric Blood & Cancer · doi:10.1002/pbc.21564 · Cited by 130
Cited by
Khoury, J. D., Solary, E., Abla, O., Akkari, Y., Alaggio, R., Apperley, J. F., Bejar, R., Berti, E., Busque, L., Chan, J. K. C., et al. (2022) · Leukemia · doi:10.1038/s41375-022-01613-1 · Cited by 4,274
Self-citationWilk, C. M., Cathomas, F., Török, O., Le Berichel, J., Park, M. D., Bigenwald, C., Heaton, G. R., Hamon, P., Troncoso, L., Scull, B. P., et al. (2023) · Immunity · doi:10.1016/j.immuni.2023.11.011 · Cited by 51
Self-citation
Metadata
- Authors
- McClain, K. L., Bigenwald, C., Collin, M., Haroche, J., Marsh, R. A., Merad, M., Picarsic, J., Ribeiro, K. B., & Allen, C. E.
- Venue
- Nature Reviews Disease Primers
- Published
- 2021-10-07
- Volume
- 7
- Issue
- 1
- Pages
- 73-73
- ISSN
- 2056-676X (ISSN-L)
- OpenAlex
- W4200432403
- Cited by
- 159
- References
- 11
- FWCI
- 3.75
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Histiocytic disorders. https://app.cochat.ai/papers/10.1038/s41572-021-00307-9
- The paper
- McClain, K. L., Bigenwald, C., Collin, M., Haroche, J., Marsh, R. A., Merad, M., Picarsic, J., Ribeiro, K. B., & Allen, C. E. (2021). Histiocytic disorders. Nature Reviews Disease Primers. https://doi.org/10.1038/s41572-021-00307-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.